Allergan (AGN) Announces Receipt of Marketing Approval in Sweden for BELKYRA as Double Chin Treatment
Tweet Send to a Friend
Allergan plc (NYSE: AGN) announced that Sweden has received the Marketing Authorisation for BELKYRA (deoxycholic acid) after being granted approval ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
